{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:46:54Z","timestamp":1793933214393,"version":"4.8.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T00:00:00Z","timestamp":1613088000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T00:00:00Z","timestamp":1613088000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Prosthetic joint infections (PJI) are a major cause of morbidity and mortality burden worldwide. While surgical management is well defined, rifampicin (RIF) dose remains controversial. The aim of our study was to determine whether Rifampicin dose impact infection outcomes in PJI due to <jats:italic>Staphylococcus<\/jats:italic> spp.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>single-center retrospective study including 411 patients with PJI due to Rifampicin-sensitive <jats:italic>Staphylococcus<\/jats:italic> spp. Rifampicine dose was categorized as follow: &lt;\u200910\u2009mg\/kg\/day, 10\u201320\u2009mg\/kg\/day or\u2009&gt;\u200920\u2009mg\/kg\/day. The primary endpoint was patient recovery, defined as being free of infection during 12\u2009months after the end of the initial antibiotic course.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>321 (78%) received RIF for the full antibiotic course. RIF dose didn\u2019t affect patients recovery rate with 67, 76 and 69% in the &lt;\u200910, 10\u201320 and\u2009&gt;\u200920\u2009mg\/kg\/day groups, respectively (<jats:italic>p<\/jats:italic>\u00a0=\u20090.083). In univariate analysis, recovery rate was significantly associated with gender (<jats:italic>p<\/jats:italic>\u00a0=\u20090.012) but not to RIF dose, or <jats:italic>Staphylococcus<\/jats:italic> phenotype (<jats:italic>aureus<\/jats:italic> or coagulase-negative). In multivariate analysis, age (p\u2009=\u20090.01) and treatment duration (<jats:italic>p<\/jats:italic>\u00a0&lt;\u2009\u00a00.01) were significantly associated with recovery rate.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>These data suggest that lower doses of RIF are as efficient and safe as the recommended high-dose French regimen in the treatment of PJI.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-021-05832-2","type":"journal-article","created":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T20:30:21Z","timestamp":1613161821000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Impact of rifampicin dose in bone and joint prosthetic device infections due to Staphylococcus spp: a retrospective single-center study in France"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1600-5036","authenticated-orcid":false,"given":"M.","family":"Tonnelier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bouras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y. El","family":"Samad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Brunschweiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-L.","family":"Schmit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Mabille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J-P","family":"Lanoix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,12]]},"reference":[{"issue":"1","key":"5832_CR1","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jhin.2012.04.025","volume":"82","author":"L Grammatico-Guillon","year":"2012","unstructured":"Grammatico-Guillon L, Baron S, Gettner S, Lecuyer A-I, Gaborit C, Rosset P, Rusch E, Bernard L. Bone and joint infections in hospitalized patients in France, 2008: clinical and economic outcomes. J Hosp Infect. 2012;82(1):40\u20138.","journal-title":"J Hosp Infect"},{"issue":"16","key":"5832_CR2","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1056\/NEJMra040181","volume":"351","author":"W Zimmerli","year":"2004","unstructured":"Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med. 2004;351(16):1645\u201354.","journal-title":"N Engl J Med"},{"issue":"24","key":"5832_CR3","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.2106\/JBJS.L.00789","volume":"95","author":"B Zmistowski","year":"2013","unstructured":"Zmistowski B, Karam JA, Durinka JB, Casper DS, Parvizi J. Periprosthetic joint infection increases the risk of one-year mortality. J Bone Joint Surg Am. 2013;95(24):2177\u201384.","journal-title":"J Bone Joint Surg Am"},{"key":"5832_CR4","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1016\/j.respe.2016.01.075","volume":"64","author":"E Laurent","year":"2016","unstructured":"Laurent E, Gras G, Druon J, Rosset P, Bernard L, Grammatico-Guillon L. \u00c9volution des infections ost\u00e9o-articulaires (IOA) en France apr\u00e8s mise en place des centres de r\u00e9f\u00e9rences des IOA complexes (CRIOAC) : PMSI 2008 versus 2013. Rev D\u00c9pid\u00e9miologie Sant\u00e9 Publique. 2016;64:S23\u20134.","journal-title":"Rev D\u00c9pid\u00e9miologie Sant\u00e9 Publique"},{"issue":"7","key":"5832_CR5","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/j.arth.2016.01.021","volume":"31","author":"BH Kapadia","year":"2016","unstructured":"Kapadia BH, Banerjee S, Cherian JJ, Bozic KJ, Mont MA. The economic impact of Periprosthetic infections after Total hip Arthroplasty at a specialized tertiary-care center. J Arthroplast. 2016;31(7):1422\u20136.","journal-title":"J Arthroplast"},{"issue":"6 Suppl","key":"5832_CR6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.arth.2010.04.011","volume":"25","author":"J Parvizi","year":"2010","unstructured":"Parvizi J, Pawasarat IM, Azzam KA, Joshi A, Hansen EN, Bozic KJ. Periprosthetic joint infection: the economic impact of methicillin-resistant infections. J Arthroplastyt. 2010;25(6 Suppl):103\u20137.","journal-title":"J Arthroplastyt"},{"issue":"1","key":"5832_CR7","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1128\/AAC.50.1.55-61.2006","volume":"50","author":"R Saginur","year":"2006","unstructured":"Saginur R, Stdenis M, Ferris W, Aaron SD, Chan F, Lee C, Ramotar K. Multiple combination bactericidal testing of staphylococcal biofilms from implant-associated infections. Antimicrob Agents Chemother janv. 2006;50(1):55\u201361.","journal-title":"Antimicrob Agents Chemother janv"},{"issue":"9","key":"5832_CR8","doi-asserted-by":"publisher","first-page":"3880","DOI":"10.1128\/AAC.00134-09","volume":"53","author":"KL LaPlante","year":"2009","unstructured":"LaPlante KL, Woodmansee S. Activities of daptomycin and vancomycin alone and in combination with rifampin and gentamicin against biofilm-forming methicillin-resistant Staphylococcus aureus isolates in an experimental model of endocarditis. Antimicrob Agents Chemother sept. 2009;53(9):3880\u20136.","journal-title":"Antimicrob Agents Chemother sept"},{"key":"5832_CR9","unstructured":"Soci\u00e9t\u00e9 de Pathologie Infectieuse de Langue Fran\u00e7aise (SPILF), Coll\u00e8ge des Universitaires de Maladies Infectieuses et Tropicales (CMIT), Groupe de Pathologie Infectieuse P\u00e9diatrique (GPIP), Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Anesth\u00e9sie et de R\u00e9animation (SFAR), Soci\u00e9t\u00e9 Fran\u00e7aise de Chirurgie Orthop\u00e9dique et Traumatologique (SOFCOT), Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Hygi\u00e8ne Hospitali\u00e8re (SFHH), Soci\u00e9t\u00e9 Fran\u00e7aise de M\u00e9decine Nucl\u00e9aire (SFMN), Soci\u00e9t\u00e9 Fran\u00e7aise de M\u00e9decine Physique et de R\u00e9adaptation (SOFMER), Soci\u00e9t\u00e9 Fran\u00e7aise de Microbiologie (SFM), Soci\u00e9t\u00e9 Fran\u00e7aise de Radiologie (SFR-Rad), Soci\u00e9t\u00e9 Fran\u00e7aise de Rhumatologie (SFR-Rhu). [Recommendations for clinical practice. Osteo-articular infection therapy according to materials used (prosthesis, implants, osteosynthesis)]. Med Mal Infect. oct 2009;39(10):745\u201374."},{"issue":"8","key":"5832_CR10","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s10096-010-0952-9","volume":"29","author":"OC El Helou","year":"2010","unstructured":"El Helou OC, Berbari EF, Lahr BD, Eckel-Passow JE, Razonable RR, Sia IG, Virk A, Walker RC, Steckelberg JM, Wilson WR, Hanssen AD, Osmon DR. Efficacy and safety of rifampin containing regimen for staphylococcal prosthetic joint infections treated with debridement and retention. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol. 2010;29(8):961\u20137.","journal-title":"Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol"},{"key":"5832_CR11","unstructured":"Optimizing combination rifampin therapy for staphylococcal osteoarticular infections - ScienceDirect [Internet]. [cit\u00e9 19 janv 2020]. Disponible sur: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1297319X12002138?via%3Dihub"},{"key":"5832_CR12","unstructured":"Influence of daily dosage and frequency of administration of rifampicin\u2013levofloxacin therapy on tolerance and effectiveness in 154 patients treated for prosthetic joint infections | SpringerLink [Internet]. [cit\u00e9 19 janv 2020]. Disponible sur: https:\/\/link.springer.com\/article\/10.1007%2Fs10096-015-2404-z"},{"issue":"6","key":"5832_CR13","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1128\/AAC.37.6.1214","volume":"37","author":"M Drancourt","year":"1993","unstructured":"Drancourt M, Stein A, Argenson JN, Zannier A, Curvale G, Raoult D. Oral rifampin plus ofloxacin for treatment of Staphylococcus-infected orthopedic implants. Antimicrob Agents Chemother. 1993;37(6):1214\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"5832_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/cid\/cis966","volume":"56","author":"DR Osmon","year":"2013","unstructured":"Osmon DR, Berbari EF, Berendt AR, Lew D, Zimmerli W, Steckelberg JM, Rao N, Hanssen A, Wilson WR. Infectious Diseases Society of America. Executive summary: diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis Off Publ Infect Dis Soc Am. 2013;56(1):1\u201310.","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"6","key":"5832_CR15","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1093\/jac\/dkh451","volume":"54","author":"F Frippiat","year":"2004","unstructured":"Frippiat F, Meunier F, Derue G. Place of newer quinolones and rifampicin in the treatment of gram-positive bone and joint infections. J Antimicrob Chemother. 2004;54(6):1158 author reply 1159.","journal-title":"J Antimicrob Chemother"},{"key":"5832_CR16","unstructured":"COL08\u201304 : Suivi th\u00e9rapeutique pharmacologique (STP) de la rifampicine (RIF) dans les infections ost\u00e9o-articulaires (IOA) - EM|consulte [Internet]. [cit\u00e9 19 janv 2020]. Disponible sur: https:\/\/www.em-consulte.com\/en\/article\/904912"},{"key":"5832_CR17","unstructured":"Lack of association between rifampicin plasma concentration and treatment-related side effects in osteoarticular infections - Roblot - 2007 - Fundamental &amp; Clinical Pharmacology - Wiley Online Library [Internet]. [cit\u00e9 19 janv 2020]. Disponible sur: https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1111\/j.1472-8206.2007.00490.x"},{"issue":"2","key":"5832_CR18","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1128\/AAC.02032-13","volume":"58","author":"F Valour","year":"2014","unstructured":"Valour F, Karsenty J, Bouaziz A, Ader F, Tod M, Lustig S, Laurent F, Ecochard R, Chidiac C, Ferry T. Antimicrobial-related severe adverse events during treatment of bone and joint infection due to methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother. 2014;58(2):746\u201355.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"5832_CR19","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1093\/cid\/cir402","volume":"53","author":"E Senneville","year":"2011","unstructured":"Senneville E, Joulie D, Legout L, Valette M, Dez\u00e8que H, Beltrand E, Rosel\u00e9 B, d\u2019Escrivan T, Lo\u00efez C, Caillaux M, Yazdanpanah Y, Maynou C, Migaud H. Outcome and predictors of treatment failure in total hip\/knee prosthetic joint infections due to Staphylococcus aureus. Clin Infect Dis Off Publ Infect Dis Soc Am. 2011;53(4):334\u201340.","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"4, Supplement","key":"5832_CR20","doi-asserted-by":"publisher","first-page":"S85","DOI":"10.1016\/j.medmal.2019.04.225","volume":"49","author":"P Randuineau","year":"2019","unstructured":"Randuineau P, Bouchand F, Matt M, Villart M, Davido B, Nich C, Dinh A. Efficacit\u00e9 et tol\u00e9rance de la rifampicine dans le traitement des infections ost\u00e9o-articulaires. M\u00e9decine Mal Infect. 2019;49(4, Supplement):S85\u20136.","journal-title":"M\u00e9decine Mal Infect"},{"issue":"8","key":"5832_CR21","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s40265-014-0222-8","volume":"74","author":"A Alsultan","year":"2014","unstructured":"Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs. 2014;74(8):839\u201354.","journal-title":"Drugs"},{"issue":"5","key":"5832_CR22","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/jcph.643","volume":"56","author":"Y Jing","year":"2016","unstructured":"Jing Y, Zhu LQ, Yang JW, Huang SP, Wang Q, Zhang J. Population pharmacokinetics of rifampicin in Chinese patients with pulmonary tuberculosis. J Clin Pharmacol. 2016;56(5):622\u20137.","journal-title":"J Clin Pharmacol"},{"key":"5832_CR23","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE). 2017;147."},{"key":"5832_CR24","volume-title":"Dur\u00e9e d\u2019Antibioth\u00e9rapie (6 versus 12 s) pour le Traitement des Infections sur Proth\u00e8se Ost\u00e9oarticulaires","author":"L Bernard","year":"2019","unstructured":"Bernard L. Dur\u00e9e d\u2019Antibioth\u00e9rapie (6 versus 12 s) pour le Traitement des Infections sur Proth\u00e8se Ost\u00e9oarticulaires, vol. 32; 2019."},{"key":"5832_CR25","unstructured":"J L-T, G E, J C, Jp H, A S, E S, C P, N B, L F, J P, Md DT, A J-S, Ja I, M S-S, A R, M F-S, M R, Jm B-E, J A. Short- Versus Long-Duration Levofloxacin Plus Rifampicin for Acute Staphylococcal Prosthetic Joint Infection Managed With Implant Retention: A Randomised Clinical Trial [Internet]. International journal of antimicrobial agents. 2016 [cit\u00e9 6 juin 2020]. Disponible sur: https:\/\/pubmed.ncbi.nlm.nih.gov\/27524103\/?from_term=prosthetic+joint+infection+rifampicin+staphylocoque&from_exact_term=prosthetic%5Btitl%5D+AND+joint%5Btitl%5D+AND+infection%5Btitl%5D+AND+rifampicin%5Btitl%5D&from_pos=1"},{"issue":"19","key":"5832_CR26","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1001\/jama.279.19.1537","volume":"279","author":"W Zimmerli","year":"1998","unstructured":"Zimmerli W, Widmer AF, Blatter M, Frei R, Ochsner PE. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA. 1998;279(19):1537\u201341.","journal-title":"JAMA"},{"issue":"6","key":"5832_CR27","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1093\/clinids\/14.6.1251","volume":"14","author":"AF Widmer","year":"1992","unstructured":"Widmer AF, Gaechter A, Ochsner PE, Zimmerli W. Antimicrobial treatment of orthopedic implant-related infections with rifampin combinations. Clin Infect Dis Off Publ Infect Dis Soc Am. 1992;14(6):1251\u20133.","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"11","key":"5832_CR28","doi-asserted-by":"publisher","first-page":"993.e7","DOI":"10.1016\/j.amjmed.2006.03.036","volume":"119","author":"J Barber\u00e1n","year":"2006","unstructured":"Barber\u00e1n J, Aguilar L, Carroquino G, Gim\u00e9nez M-J, S\u00e1nchez B, Mart\u00ednez D, Prieto J. Conservative treatment of staphylococcal prosthetic joint infections in elderly patients. Am J Med. 2006;119(11):993.e7\u201310.","journal-title":"Am J Med"},{"key":"5832_CR29","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1111\/j.1469-0691.2006.01463.x","volume":"12","author":"A Soriano","year":"2006","unstructured":"Soriano A, Garcia S, Bori G, et al. Treatment of acute post-surgical infection of joint arthroplasty. Clin Microbiol Infect. 2006;12:930\u20133.","journal-title":"Clin Microbiol Infect"},{"key":"5832_CR30","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1111\/j.1469-0691.2007.01691.x","volume":"13","author":"CA Aboltins","year":"2007","unstructured":"Aboltins CA, Page MA, Buising KL, et al. Treatment of staphylococcal prosthetic joint infections with debridement, prosthesis retention and oral rifampicin and fusidic acid. Clin Microbiol Infect. 2007;13:586\u201391.","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"5832_CR31","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/jac\/39.2.235","volume":"39","author":"M Drancourt","year":"1997","unstructured":"Drancourt M, Stein A, Argenson JN, Roiron R, Groulier P, Raoult D. Oral treatment of Staphylococcus spp infected orthopaedic implants with fusidic acid or ofloxacin in combination with rifampicin. J Antimicrob Chemother. 1997;39(2):235\u201340.","journal-title":"J Antimicrob Chemother"},{"key":"5832_CR32","doi-asserted-by":"crossref","unstructured":"Seijger C, Hoefsloot W, Bergsma-de Guchteneire I, te Brake L, van Ingen J, Kuipers S, van Crevel R, Aarnoutse R, Boeree M, Magis-Escurra C. High-dose rifampicin in tuberculosis: Experiences from a Dutch tuberculosis centre. PLoS ONE [Internet]. 14 mars 2019 [cit\u00e9 6 juin 2020];14(3). Disponible sur: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6417786\/","DOI":"10.1371\/journal.pone.0213718"},{"key":"5832_CR33","unstructured":"Mj B, Ah D, R D, K N, J du B, A V, Pp P, Sh G, Td M, M H, N H, S R, D van S, J van I, C M-E, D B, G P van B, Re A. A Dose-Ranging Trial to Optimize the Dose of Rifampin in the Treatment of Tuberculosis [Internet]. American journal of respiratory and critical care medicine. 2015 [cit\u00e9 6 juin 2020]. Disponible sur: https:\/\/pubmed.ncbi.nlm.nih.gov\/25654354\/"},{"issue":"2","key":"5832_CR34","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1517\/14740338.2012.632631","volume":"11","author":"M Hagihara","year":"2012","unstructured":"Hagihara M, Crandon JL, Nicolau DP. The efficacy and safety of antibiotic combination therapy for infections caused by gram-positive and gram-negative organisms. Expert Opin Drug Saf. 2012;11(2):221\u201333.","journal-title":"Expert Opin Drug Saf"},{"key":"5832_CR35","unstructured":"Population pharmacokinetics of rifampicin in adult patients with osteoarticular infections: interaction with fusidic acid [Internet]. [cit\u00e9 19 janv 2020]. Disponible sur: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5401979\/"},{"issue":"12","key":"5832_CR36","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.1093\/jac\/dkv268","volume":"70","author":"K-Y Seng","year":"2015","unstructured":"Seng K-Y, Hee K-H, Soon G-H, Chew N, Khoo SH, Lee LS-U. Population pharmacokinetics of rifampicin and 25-deacetyl-rifampicin in healthy Asian adults. J Antimicrob Chemother. d\u00e9c. 2015;70(12):3298\u2013306.","journal-title":"J Antimicrob Chemother. d\u00e9c"},{"key":"5832_CR37","doi-asserted-by":"crossref","unstructured":"Grosset J, Leventis S. Adverse effects of rifampin. Rev Infect Dis. 1983;5(Suppl 3):S440\u201350.","DOI":"10.1093\/clinids\/5.Supplement_3.S440"},{"issue":"5","key":"5832_CR38","first-page":"433","volume":"12","author":"RR Laffer","year":"2006","unstructured":"Laffer RR, Graber P, Ochsner PE, Zimmerli W. Outcome of prosthetic knee-associated infection: evaluation of 40 consecutive episodes at a single Centre. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis mai. 2006;12(5):433\u20139.","journal-title":"Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis mai"},{"key":"5832_CR39","unstructured":"Management of infections of osteoarticular prosthesis. - PubMed - NCBI [Internet]. [cit\u00e9 19 janv 2020]. Disponible sur: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16669932"},{"issue":"10","key":"5832_CR40","first-page":"843","volume":"11","author":"J-E Berdal","year":"2005","unstructured":"Berdal J-E, Skr\u00e5mm I, Mowinckel P, Gulbrandsen P, Bj\u00f8rnholt JV. Use of rifampicin and ciprofloxacin combination therapy after surgical debridement in the treatment of early manifestation prosthetic joint infections. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis oct. 2005;11(10):843\u20135.","journal-title":"Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis oct"},{"issue":"6","key":"5832_CR41","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1080\/17453670710014527","volume":"78","author":"PFM Choong","year":"2007","unstructured":"Choong PFM, Dowsey MM, Carr D, Daffy J, Stanley P. Risk factors associated with acute hip prosthetic joint infections and outcome of treatment with a rifampinbased regimen. Acta Orthop. 2007;78(6):755\u201365.","journal-title":"Acta Orthop"},{"issue":"3","key":"5832_CR42","first-page":"439","volume":"17","author":"F Vilchez","year":"2011","unstructured":"Vilchez F, Mart\u00ednez-Pastor JC, Garc\u00eda-Ramiro S, Bori G, Macul\u00e9 F, Sierra J, Font L, Mensa J, Soriano A. Outcome and predictors of treatment failure in early post-surgical prosthetic joint infections due to Staphylococcus aureus treated with debridement. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2011;17(3):439\u201344.","journal-title":"Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-05832-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-021-05832-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-05832-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T20:34:55Z","timestamp":1613162095000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-05832-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,12]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["5832"],"URL":"https:\/\/doi.org\/10.1186\/s12879-021-05832-2","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,12]]},"assertion":[{"value":"1 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the CNIL agency (Commission Nationale Informatique et Libert\u00e9) in compliance with local and national regulations, under the number PI2019_843_0068. Data used in this study was anonymised before its use.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"174"}}